Journal of Gastroenterology

, Volume 53, Issue 5, pp 679–688 | Cite as

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection

  • Stefan ZeuzemEmail author
  • Lawrence Serfaty
  • John Vierling
  • Wendy Cheng
  • Jacob George
  • Jan Sperl
  • Simone Strasser
  • Hiromitsu Kumada
  • Peggy Hwang
  • Michael Robertson
  • Janice Wahl
  • Eliav Barr
  • Rohit Talwani
  • Heather Platt
Original Article—Liver, Pancreas, and Biliary Tract



Genotype 1b (GT1b) is the most common subtype of the hepatitis C virus (HCV). We present an integrated analysis of 1070 participants with HCV GT1b infection from 30 countries who received elbasvir/grazoprevir for 12 weeks.


This is a retrospective analysis of data from participants with chronic HCV GT1b infection enrolled in 11 phase II/III clinical trials. All participants received elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks. The primary end point of all studies was sustained virologic response 12 weeks after completion of therapy (SVR12, HCV RNA < 15 IU/ml).


SVR12 was 97.2% (1040/1070). Of the 30 participants who failed to attain SVR12, 15 relapsed and 15 had nonvirologic failure. Among participant subgroups, SVR12 was high in those with compensated cirrhosis (188/189, 99.5%), HIV co-infection (51/54, 94.4%), and baseline viral load > 800,000 IU/ml (705/728, 96.8%). Resistance-associated substitutions (RASs) at NS5A positions 28, 30, 31, or 93 were present in 21.6% of participants at baseline. SVR12 was 99.6% (820/823) in participants without baseline NS5A RASs and 94.7% (215/227) in those with baseline NS5A RASs. Serious adverse events occurred in 3.2% (34/1070) of participants, nine of which occurred after study medication was completed.


Elbasvir/grazoprevir for 12 weeks represents an effective treatment option for participants with HCV GT1b infection. SVR12 was high in all participant subgroups, including those with compensated cirrhosis, HIV co-infection, and high baseline viral load. identifiers

The trials discussed in this paper were registered with as the following: NCT02092350 (C-SURFER), NCT02105662 (C-EDGE Co-Infection), NCT02105467 (C-EDGE treatment-naive), NCT02105701 (C-EDGE treatment-experienced), NCT01717326 (C-WORTHy), NCT02251990 (C-CORAL), NCT02105688 (C-EDGE COSTAR), NCT02252016 (C-EDGE IBLD), NCT02115321 (C-SALT), NCT02203149 (Japan phase 2/3 study), NCT02358044 (C-EDGE Head-2-Head).


Hepatitis Retrospective Therapy 



The authors extend their gratitude to the participants, their families, investigators and site personnel who participated in this study. The studies included in this analysis were funded by Merck & Co., Inc. Medical writing and editorial assistance was provided by Tim Ibbotson, PhD, of ApotheCom and funded by Merck & Co., Inc., Kenilworth, NJ, USA.


These studies were funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Compliance with ethical standards

Conflict of interest

Stefan Zeuzem has served a consultant for AbbVie, BMS, Gilead, Janssen, and Merck/MSD. Lawrence Serfaty has received personal fees from MSD, Gilead, Janssen, Bristol-Myers Squibb, and AbbVie. John Vierling has received grants or other payments from AbbVie, Bristol-Myers Squibb, Conatus, Genentech, Genentech, Gilead, Gilead, Merck, Novartis, and Sundise. Wendy Cheng has received personal fees from Merck for participation on a Medical Education Expert Input Forum. Jacob George has received personal fees from MSD, AbbVie, Gilead, Pharmaxis, and Bristol-Myers Squibb. Jan Sperl has received research grants from Gilead and Janssen-Cilag and personal fees for speaker/advisor roles with Gilead, Janssen-Cilag, Merck, and AbbVie. Simone Strasser has received personal fees from MSD/Merck, Gilead Sciences, AbbVie, Bristol-Myers Squibb, and Janssen. Hiromitsu Kumada has received grants from MSD KK during the conduct of the study and personal fees from MSD KK, GSK, Tanabe-Mitsubishi, Bristol-Myers Squibb, and Janssen, and has a patent SRL licensed. Peggy Hwang, Michael Robertson, Janice Wahl, Eliav Barr, Rohit Talwani, and Heather Platt are employees of and hold stock in Merck & Co., Inc.

Supplementary material

535_2018_1429_MOESM1_ESM.pdf (149 kb)
Supplementary material 1 (PDF 148 kb)
535_2018_1429_MOESM2_ESM.pdf (170 kb)
Supplementary material 2 (PDF 169 kb)
535_2018_1429_MOESM3_ESM.pdf (98 kb)
Supplementary material 3 (PDF 97 kb)
535_2018_1429_MOESM4_ESM.pdf (82 kb)
Supplementary material 4 (PDF 81 kb)


  1. 1.
    Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):S45–57.CrossRefPubMedGoogle Scholar
  2. 2.
    AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–54.CrossRefGoogle Scholar
  3. 3.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.CrossRefGoogle Scholar
  4. 4.
    Kowdley KV, Gordon SC, Reddy KR, for the ION-3 Investigators, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.CrossRefPubMedGoogle Scholar
  5. 5.
    Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Feld JJ, Jacobson IM, Hézode C, for the ASTRAL-1 Investigators, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.CrossRefPubMedGoogle Scholar
  7. 7.
    Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Dore GJ, Altice F, Litwin AH, et al. Elbasvir–grazoprevir to treat hepatitis C virus in persons receiving opioid agonist therapy: a randomized trial. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. Ann Intern Med. 2016;65(9):625–34.CrossRefGoogle Scholar
  11. 11.
    Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075–86.CrossRefPubMedGoogle Scholar
  12. 12.
    Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–97.CrossRefPubMedGoogle Scholar
  13. 13.
    Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8(12):1930–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56(8):4161–7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kwo P, Gane E, Peng C-Y, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164–75.CrossRefPubMedGoogle Scholar
  16. 16.
    Zepatier (elbasvir and grazoprevir) (package insert). Merck & Co., Inc.: Whitehouse Station, 2016.Google Scholar
  17. 17.
    European Medicines Agency. Zepatier (elbasvir/grazoprevir): EPAR summary for the public. Accessed 27 Mar 2017.
  18. 18.
  19. 19.
    Sperl J, Horvath G, Halota W, et al. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J Hepatol. 2016;65(6):1112–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol. 2017;52(4):520–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Hezode C, Colombo M, Spengler U, et al. C-EDGE IBLD: efficacy and safety of elbasvir/grazoprevir in subjects with chronic hepatitis C virus infection and inherited blood disorders. J Hepatol. 2016;58:S342.Google Scholar
  22. 22.
    Afdhal N, Zeuzem S, Kwo P, for the ION-1 Investigators, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.CrossRefPubMedGoogle Scholar
  23. 23.
    Vierling JM, Kugelmas M, Lawitz E, et al. Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection. J Hepatol. 2015;62(suppl 2):S618 (abstract P0769).CrossRefGoogle Scholar
  24. 24.
    Harvoni (ledipasvir and sofosbuvir) package insert. Foster City: Gilead Sciences; 2016.Google Scholar
  25. 25.
    European Medicines Agency. Harvoni (ledipasvir/sofosbuvir) (summary of product characteristics). Accessed 27 Mar 2017.
  26. 26.
    Dusheiko GM, Manns MP, Vierling JM, et al. Safety and tolerability of grazoprevir/elbasvir in patients with chronic hepatitis C: integrated analysis of phase 2–3 trials. Hepatology. 2015;62(suppl 1):562A (abstract 712).Google Scholar
  27. 27.
    Hernandez D, Yu F, Huang X, et al. Impact of pre-existing NS5A-L31 or -Y93H minor variants on response rates in patients infected with HCV genotype-1b treated with daclatasvir/asunaprevir. Adv Ther. 2016;33(7):1169–79.CrossRefPubMedGoogle Scholar
  28. 28.
    Kao J-H, Lee Y-J, Heo J, et al. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016;36(10):1433–41.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  • Stefan Zeuzem
    • 1
    Email author
  • Lawrence Serfaty
    • 2
  • John Vierling
    • 3
  • Wendy Cheng
    • 4
  • Jacob George
    • 5
  • Jan Sperl
    • 6
  • Simone Strasser
    • 7
  • Hiromitsu Kumada
    • 8
  • Peggy Hwang
    • 9
  • Michael Robertson
    • 9
  • Janice Wahl
    • 9
  • Eliav Barr
    • 9
  • Rohit Talwani
    • 9
  • Heather Platt
    • 9
  1. 1.Goethe University HospitalFrankfurtGermany
  2. 2.Service d’Hépatologie, Hôpital Saint-AntoineUniversité Pierre and Marie CurieParisFrance
  3. 3.Baylor College of Medicine, Advanced Liver TherapiesHoustonUSA
  4. 4.Department of Gastroenterology and HepatologyRoyal Perth HospitalPerthAustralia
  5. 5.Storr Liver Centre, Westmead Institute for Medical ResearchWestmead Hospital and University of SydneySydneyAustralia
  6. 6.Institute for Clinical and Experimental Medicine (IKEM)PragueCzech Republic
  7. 7.AW Morrow Gastroenterology and Liver CentreRoyal Prince Alfred HospitalSydneyAustralia
  8. 8.Department of HepatologyToranomon HospitalTokyoJapan
  9. 9.Merck & Co., Inc.KenilworthUSA

Personalised recommendations